Takeda (TAK) announced that the FDA has approved Gammagard Liquid ERC with less than or equal to two microgram/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin therapy with low immunoglobulin A content, as replacement therapy for people two years of age and older with primary immunodeficiency.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.